194 related articles for article (PubMed ID: 33926484)
41. Fatty acid oxidation is associated with proliferation and prognosis in breast and other cancers.
Aiderus A; Black MA; Dunbier AK
BMC Cancer; 2018 Aug; 18(1):805. PubMed ID: 30092766
[TBL] [Abstract][Full Text] [Related]
42. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
43. BH3 mimetic ABT-737 induces apoptosis in CD34
Rao J; Li F; Zhang RY; Zhou HH; Chen GA
Asia Pac J Clin Oncol; 2017 Apr; 13(2):e144-e152. PubMed ID: 26552712
[TBL] [Abstract][Full Text] [Related]
44. PD-L1 stimulation can promote proliferation and survival of leukemic cells by influencing glucose and fatty acid metabolism in acute myeloid leukemia.
Soltani M; Ghanadian M; Ghezelbash B; Shokouhi A; Zamyatnin AA; Bazhin AV; Ganjalikhani-Hakemi M
BMC Cancer; 2023 May; 23(1):447. PubMed ID: 37193972
[TBL] [Abstract][Full Text] [Related]
45. TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia.
Qian S; Li J; Hong M; Zhu Y; Zhao H; Xie Y; Huang J; Lian Y; Li Y; Wang S; Mao J; Chen Y
J Hematol Oncol; 2016 Nov; 9(1):128. PubMed ID: 27884166
[TBL] [Abstract][Full Text] [Related]
46. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
Jacque N; Ronchetti AM; Larrue C; Meunier G; Birsen R; Willems L; Saland E; Decroocq J; Maciel TT; Lambert M; Poulain L; Hospital MA; Sujobert P; Joseph L; Chapuis N; Lacombe C; Moura IC; Demo S; Sarry JE; Recher C; Mayeux P; Tamburini J; Bouscary D
Blood; 2015 Sep; 126(11):1346-56. PubMed ID: 26186940
[TBL] [Abstract][Full Text] [Related]
47. The plasma lipidome in acute myeloid leukemia at diagnosis in relation to clinical disease features.
Pabst T; Kortz L; Fiedler GM; Ceglarek U; Idle JR; Beyoğlu D
BBA Clin; 2017 Jun; 7():105-114. PubMed ID: 28331812
[TBL] [Abstract][Full Text] [Related]
48. Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.
Ruvolo PP; Ruvolo VR; Benton CB; AlRawi A; Burks JK; Schober W; Rolke J; Tidmarsh G; Hail N; Davis RE; Andreeff M
Biochim Biophys Acta; 2016 Apr; 1863(4):562-71. PubMed ID: 26704388
[TBL] [Abstract][Full Text] [Related]
49. LukS-PV induces mitochondrial-mediated apoptosis and G0/G1 cell cycle arrest in human acute myeloid leukemia THP-1 cells.
Bu S; Xie Q; Chang W; Huo X; Chen F; Ma X
Int J Biochem Cell Biol; 2013 Aug; 45(8):1531-7. PubMed ID: 23702031
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia.
Jiang X; Jiang L; Cheng J; Chen F; Ni J; Yin C; Wang Q; Wang Z; Fang D; Yi Z; Yu G; Zhong Q; Carter BZ; Meng F
J Transl Med; 2021 Mar; 19(1):117. PubMed ID: 33743723
[TBL] [Abstract][Full Text] [Related]
51. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
Naqvi K; Konopleva M; Ravandi F
Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
[TBL] [Abstract][Full Text] [Related]
52. Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia.
Del Poeta G; Bruno A; Del Principe MI; Venditti A; Maurillo L; Buccisano F; Stasi R; Neri B; Luciano F; Siniscalchi A; de Fabritiis P; Amadori S
Curr Cancer Drug Targets; 2008 May; 8(3):207-22. PubMed ID: 18473734
[TBL] [Abstract][Full Text] [Related]
53. Targeting CPT1A enhances metabolic therapy in human melanoma cells with the BRAF V600E mutation.
Sung GJ; Choi HK; Kwak S; Song JH; Ko H; Yoon HG; Kang HB; Choi KC
Int J Biochem Cell Biol; 2016 Dec; 81(Pt A):76-81. PubMed ID: 27793752
[TBL] [Abstract][Full Text] [Related]
54. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
Tan M; Zhang Q; Yuan X; Chen Y; Wu Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525
[TBL] [Abstract][Full Text] [Related]
55. The CCL2/CCR2 Axis Affects Transmigration and Proliferation but Not Resistance to Chemotherapy of Acute Myeloid Leukemia Cells.
Macanas-Pirard P; Quezada T; Navarrete L; Broekhuizen R; Leisewitz A; Nervi B; Ramírez PA
PLoS One; 2017; 12(1):e0168888. PubMed ID: 28045930
[TBL] [Abstract][Full Text] [Related]
56. CPT1A and fatty acid β-oxidation are essential for tumor cell growth and survival in hormone receptor-positive breast cancer.
Jariwala N; Mehta GA; Bhatt V; Hussein S; Parker KA; Yunus N; Parker JS; Guo JY; Gatza ML
NAR Cancer; 2021 Sep; 3(3):zcab035. PubMed ID: 34514415
[TBL] [Abstract][Full Text] [Related]
57. Ceramide Analogue SACLAC Modulates Sphingolipid Levels and
Pearson JM; Tan SF; Sharma A; Annageldiyev C; Fox TE; Abad JL; Fabrias G; Desai D; Amin S; Wang HG; Cabot MC; Claxton DF; Kester M; Feith DJ; Loughran TP
Mol Cancer Res; 2020 Mar; 18(3):352-363. PubMed ID: 31744877
[TBL] [Abstract][Full Text] [Related]
58. Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells.
Steinwascher S; Nugues AL; Schoeneberger H; Fulda S
Cancer Lett; 2015 Sep; 366(1):32-43. PubMed ID: 26028172
[TBL] [Abstract][Full Text] [Related]
59. Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells.
Wang R; Xia L; Gabrilove J; Waxman S; Jing Y
Clin Cancer Res; 2016 Mar; 22(5):1211-21. PubMed ID: 26459180
[TBL] [Abstract][Full Text] [Related]
60. Nobiletin Down-Regulates c-KIT Gene Expression and Exerts Antileukemic Effects on Human Acute Myeloid Leukemia Cells.
Chen PY; Chen YT; Gao WY; Wu MJ; Yen JH
J Agric Food Chem; 2018 Dec; 66(51):13423-13434. PubMed ID: 30507186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
